This post garnered exceptional interest. Here is a quote on some of the challenges presented by GLP-1 drugs. "GLP-1 drugs deliver impressive short-term results (Diabetes, Obesity and Metabolism 2022), but studies show discontinuation leads to rapid regain, often 50 to 100 percent of lost weight within 12 months (Rubino, JAMA 2022). Dropout rates run high, driven by side effects, cost, and access barriers (Rodriguez, JAMA 2022). Even sustained use carries risks like muscle loss (15 to 40 percent –ScienceInsights, 2025)and long-term risks (Healthhoper 2026)." Read the full article to see how Humaculture suggests addressing this challenge through integrative soil cultivation: humaculture.com/2026/02/05/b… #Humaculture #MeritBasedOpportunity #PerscriptionDrugs #IntegrativeFirst @InsuranceCollab